Rafael (NYSE:RFL) Releases Earnings Results

Rafael (NYSE:RFL) issued its earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, FiscalAI reports. Rafael had a negative return on equity of 41.27% and a negative net margin of 3,321.74%. The company had revenue of $0.24 million for the quarter.

Rafael Stock Down 1.3%

RFL stock traded down $0.01 during trading on Friday, reaching $1.10. The stock had a trading volume of 53,773 shares, compared to its average volume of 134,570. Rafael has a one year low of $1.08 and a one year high of $3.96. The company’s 50 day moving average is $1.86 and its two-hundred day moving average is $1.69. The company has a market capitalization of $57.46 million, a price-to-earnings ratio of -1.62 and a beta of 0.35.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Rafael stock. Kahn Brothers Group Inc. purchased a new stake in shares of Rafael Holdings, Inc. (NYSE:RFL) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 150,493 shares of the company’s stock, valued at approximately $494,000. Kahn Brothers Group Inc. owned 0.29% of Rafael as of its most recent filing with the Securities & Exchange Commission. 11.30% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

RFL has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Rafael to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rafael in a report on Tuesday, August 25th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Rafael

Rafael Holdings, Inc (NYSE:RFL) is a diversified holding company with interests in biotechnology and commercial real estate. Through its life sciences operations, the company has focused on developing potential treatments for cancer and other serious diseases, including therapies designed to target the metabolism of cancer cells.

Rafael’s biotechnology activities have been conducted primarily through Rafael Pharmaceuticals, which has researched investigational drug candidates such as devimistat (also known as CPI-613).